Product Code: A05105
The global pulmonary arterial hypertension treatment market was valued at $7,177.81 million in 2021, and is projected to reach $11,968.60 million by 2031, registering a CAGR of 5.2% from 2022 to 2031.
Pulmonary Arterial Hypertension (PAH) is a medical condition defined as the endothelial dysfunction and vascular remodeling block the tiny pulmonary arteries, increasing pulmonary vascular resistance and pulmonary pressures which results in reduced cardiac output, right heart failure and finally death of the patient. Pulmonary arterial infection can occur due to number of conditions, including those that are transferred through generations, like connective tissue disease, HIV infection, portal hypertension (liver disease), sickle cell disease, and congenital heart disease. The symptoms associated with pulmonary arterial hypertension are blue lips and skin (cyanosis), chest pressure or pain, dizziness, weariness, shortness of breath (dyspnea) while exercising, and or at rest. The drugs such as sildenafil (revatio, viagra) and tadalafil (adcirca) are used to treat patients with pulmonary arterial hypertension.
The key factors that drive the growth of pulmonary arterial hypertension treatment market are increase in the prevalence of geriatric population affected with pulmonary arterial hypertension; rise in prevalence of HIV cases and surge in healthcare expenditure boost the market growth. According to National Center for Biotechnology Information in 2020, reported that the patient with HIV positive having risk of 0.5% higher prevalence of pulmonary arterial hypertension (PAH) than HIV-negative individuals with a difference of around 2500 times.
In addition, according to data from an article in the Cardiovascular Diagnosis and Therapy Journal published in 2020, (which discusses the global epidemiology of pulmonary hypertension with a focus on sub-Saharan Africa and low- and middle-income countries), it is estimated that 80% of patients with pulmonary hypertension below age group 65, who have a high risk of congenital heart disease, rheumatic heart disease, and HIV, live in low and middle-income countries.
In addition, rise in number of product approvals and key strategic developments by regulatory authorities for effective treatment of pulmonary artery hypertension contribute toward market growth. For instance, Janssen Pharmaceutical Companies of Johnson & Johnson, is a one of the key players involved in manufacturing and development of drugs for pulmonary arterial hypertension. It has announced the submission of product approval application to FDA for the use of UPTRAVI product intravenously to cure the patient with pulmonary artery hypertension. However, side effects associated with drug based pulmonary arterial hypertension treatment restricts the market growth during forecast period. Moreover, rise in growth potential in developing countries offers lucrative opportunities to market players operating in the pulmonary arterial hypertension treatment market.
The pulmonary arterial hypertension treatment market is segmented into drug type, type, route of administration and region. On the basis of drug type, the market is categorized into endothelin receptor antagonists (ERAs), PDE-5 inhibitors, prostacyclin, and prostacyclin analogs and sGC stimulators. On the basis of type, it is further bifurcated into branded and generic. The branded segment is further classified into retail pharmacy, hospital pharmacy and online pharmacy. The generic segment is further classified into retail pharmacy, hospital pharmacy and online pharmacy. On the basis of route of administration, the market is further classified into oral, intravenous/ subcutaneous, and inhalational. On the basis of region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Some of the major companies that operate in the global pulmonary arterial hypertension treatment market are Bayer AG, GlaxoSmithKline Plc, Gilead Sciences, Inc., Johnson & Johnson, Lupin Pharmaceuticals, Inc., Sandoz Inc. (Novartis), Sun Pharmaceutical Industries, Ltd., Teva Pharmaceutical Industries Ltd., United Therapeutics Corporation and Viatris Inc.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the pulmonary arterial hypertension treatment market analysis from 2021 to 2031 to identify the prevailing pulmonary arterial hypertension treatment market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the pulmonary arterial hypertension treatment market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global pulmonary arterial hypertension treatment market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By by Drug Type
- Endothelin Receptor Antagonists (ERAs)
- PDE-5 Inhibitors
- Prostacyclin and Prostacyclin Analogs
- SGC Stimulators
By Type
- Branded
- Distribution Channel
- Retail Pharmacy
- Hospital Pharmacy
- Online Pharmacy
- Generics
- Distribution Channel
- Retail Pharmacy
- Hospital Pharmacy
- Online Pharmacy
By Route of Administration
- Oral
- Intravenous/ subcutaneous
- Inhalational
By Region
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest Of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest Of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest Of LAMEA
- Key Market Players
- United Therapeutics Corporation
- Bayer AG
- Gilead Sciences, Inc.
- Johnson & Johnson
- Viatris Inc.
- GlaxoSmithKline
- Novartis
- Lupin Pharmaceuticals, Inc.
- Sun Pharmaceutical Industries, Inc.
- Teva Pharmaceutical Industries Ltd.
TABLE OF CONTENTS
CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter's five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY BY DRUG TYPE
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Endothelin Receptor Antagonists (ERAs)
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
- 4.3 PDE-5 Inhibitors
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
- 4.4 Prostacyclin and Prostacyclin Analogs
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market analysis by country
- 4.5 SGC Stimulators
- 4.5.1 Key market trends, growth factors and opportunities
- 4.5.2 Market size and forecast, by region
- 4.5.3 Market analysis by country
CHAPTER 5: PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY TYPE
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 Branded
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
- 5.2.4 Branded Pulmonary Arterial Hypertension Treatment Market by Distribution Channel
- 5.2.4.1 Retail Pharmacy Market size and forecast, by region
- 5.2.4.2 Hospital Pharmacy Market size and forecast, by region
- 5.2.4.3 Online Pharmacy Market size and forecast, by region
- 5.3 Generics
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
- 5.3.4 Generics Pulmonary Arterial Hypertension Treatment Market by Distribution Channel
- 5.3.4.1 Retail Pharmacy Market size and forecast, by region
- 5.3.4.2 Hospital Pharmacy Market size and forecast, by region
- 5.3.4.3 Online Pharmacy Market size and forecast, by region
CHAPTER 6: PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 Oral
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
- 6.3 Intravenous/ subcutaneous
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
- 6.4 Inhalational
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market analysis by country
CHAPTER 7: PULMONARY ARTERIAL HYPERTENSION TREATMENT MARKET, BY REGION
- 7.1 Overview
- 7.1.1 Market size and forecast
- 7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by by Drug Type
- 7.2.3 North America Market size and forecast, by Type
- 7.2.3.1 North America Branded Pulmonary Arterial Hypertension Treatment Market by Distribution Channel
- 7.2.3.2 North America Generics Pulmonary Arterial Hypertension Treatment Market by Distribution Channel
- 7.2.4 North America Market size and forecast, by Route of Administration
- 7.2.5 North America Market size and forecast, by country
- 7.2.5.1 U.S.
- 7.2.5.1.1 Market size and forecast, by by Drug Type
- 7.2.5.1.2 Market size and forecast, by Type
- 7.2.5.1.3 Market size and forecast, by Route of Administration
- 7.2.5.2 Canada
- 7.2.5.2.1 Market size and forecast, by by Drug Type
- 7.2.5.2.2 Market size and forecast, by Type
- 7.2.5.2.3 Market size and forecast, by Route of Administration
- 7.2.5.3 Mexico
- 7.2.5.3.1 Market size and forecast, by by Drug Type
- 7.2.5.3.2 Market size and forecast, by Type
- 7.2.5.3.3 Market size and forecast, by Route of Administration
- 7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by by Drug Type
- 7.3.3 Europe Market size and forecast, by Type
- 7.3.3.1 Europe Branded Pulmonary Arterial Hypertension Treatment Market by Distribution Channel
- 7.3.3.2 Europe Generics Pulmonary Arterial Hypertension Treatment Market by Distribution Channel
- 7.3.4 Europe Market size and forecast, by Route of Administration
- 7.3.5 Europe Market size and forecast, by country
- 7.3.5.1 Germany
- 7.3.5.1.1 Market size and forecast, by by Drug Type
- 7.3.5.1.2 Market size and forecast, by Type
- 7.3.5.1.3 Market size and forecast, by Route of Administration
- 7.3.5.2 France
- 7.3.5.2.1 Market size and forecast, by by Drug Type
- 7.3.5.2.2 Market size and forecast, by Type
- 7.3.5.2.3 Market size and forecast, by Route of Administration
- 7.3.5.3 UK
- 7.3.5.3.1 Market size and forecast, by by Drug Type
- 7.3.5.3.2 Market size and forecast, by Type
- 7.3.5.3.3 Market size and forecast, by Route of Administration
- 7.3.5.4 Italy
- 7.3.5.4.1 Market size and forecast, by by Drug Type
- 7.3.5.4.2 Market size and forecast, by Type
- 7.3.5.4.3 Market size and forecast, by Route of Administration
- 7.3.5.5 Spain
- 7.3.5.5.1 Market size and forecast, by by Drug Type
- 7.3.5.5.2 Market size and forecast, by Type
- 7.3.5.5.3 Market size and forecast, by Route of Administration
- 7.3.5.6 Rest of Europe
- 7.3.5.6.1 Market size and forecast, by by Drug Type
- 7.3.5.6.2 Market size and forecast, by Type
- 7.3.5.6.3 Market size and forecast, by Route of Administration
- 7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by by Drug Type
- 7.4.3 Asia-Pacific Market size and forecast, by Type
- 7.4.3.1 Asia-Pacific Branded Pulmonary Arterial Hypertension Treatment Market by Distribution Channel
- 7.4.3.2 Asia-Pacific Generics Pulmonary Arterial Hypertension Treatment Market by Distribution Channel
- 7.4.4 Asia-Pacific Market size and forecast, by Route of Administration
- 7.4.5 Asia-Pacific Market size and forecast, by country
- 7.4.5.1 China
- 7.4.5.1.1 Market size and forecast, by by Drug Type
- 7.4.5.1.2 Market size and forecast, by Type
- 7.4.5.1.3 Market size and forecast, by Route of Administration
- 7.4.5.2 Japan
- 7.4.5.2.1 Market size and forecast, by by Drug Type
- 7.4.5.2.2 Market size and forecast, by Type
- 7.4.5.2.3 Market size and forecast, by Route of Administration
- 7.4.5.3 India
- 7.4.5.3.1 Market size and forecast, by by Drug Type
- 7.4.5.3.2 Market size and forecast, by Type
- 7.4.5.3.3 Market size and forecast, by Route of Administration
- 7.4.5.4 Australia
- 7.4.5.4.1 Market size and forecast, by by Drug Type
- 7.4.5.4.2 Market size and forecast, by Type
- 7.4.5.4.3 Market size and forecast, by Route of Administration
- 7.4.5.5 South Korea
- 7.4.5.5.1 Market size and forecast, by by Drug Type
- 7.4.5.5.2 Market size and forecast, by Type
- 7.4.5.5.3 Market size and forecast, by Route of Administration
- 7.4.5.6 Rest of Asia-Pacific
- 7.4.5.6.1 Market size and forecast, by by Drug Type
- 7.4.5.6.2 Market size and forecast, by Type
- 7.4.5.6.3 Market size and forecast, by Route of Administration
- 7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by by Drug Type
- 7.5.3 LAMEA Market size and forecast, by Type
- 7.5.3.1 LAMEA Branded Pulmonary Arterial Hypertension Treatment Market by Distribution Channel
- 7.5.3.2 LAMEA Generics Pulmonary Arterial Hypertension Treatment Market by Distribution Channel
- 7.5.4 LAMEA Market size and forecast, by Route of Administration
- 7.5.5 LAMEA Market size and forecast, by country
- 7.5.5.1 Brazil
- 7.5.5.1.1 Market size and forecast, by by Drug Type
- 7.5.5.1.2 Market size and forecast, by Type
- 7.5.5.1.3 Market size and forecast, by Route of Administration
- 7.5.5.2 Saudi Arabia
- 7.5.5.2.1 Market size and forecast, by by Drug Type
- 7.5.5.2.2 Market size and forecast, by Type
- 7.5.5.2.3 Market size and forecast, by Route of Administration
- 7.5.5.3 South Africa
- 7.5.5.3.1 Market size and forecast, by by Drug Type
- 7.5.5.3.2 Market size and forecast, by Type
- 7.5.5.3.3 Market size and forecast, by Route of Administration
- 7.5.5.4 Rest of LAMEA
- 7.5.5.4.1 Market size and forecast, by by Drug Type
- 7.5.5.4.2 Market size and forecast, by Type
- 7.5.5.4.3 Market size and forecast, by Route of Administration
CHAPTER 8: COMPANY LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Key developments
CHAPTER 9: COMPANY PROFILES
- 9.1 United Therapeutics Corporation
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
- 9.2 Bayer AG
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
- 9.3 Gilead Sciences, Inc.
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
- 9.4 Johnson & Johnson
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
- 9.5 Viatris Inc.
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
- 9.6 GlaxoSmithKline
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
- 9.7 Novartis
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
- 9.8 Lupin Pharmaceuticals, Inc.
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
- 9.9 Sun Pharmaceutical Industries, Inc.
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
- 9.10 Teva Pharmaceutical Industries Ltd.
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments